Discover
AVB-500 / AraviveAravive announces dose escalation of AVB-500 in recurrent platinum resistant ovarian cancer phase 1b trial (GlobeNewswire) - Feb 18, 2020 - "Aravive, Inc...announced that the independent Data Monitoring Committtee (DMC) has reviewed the open-label data following the first 28-day treatment cycle for the three patients in each of the two 15 mg/kg dosing cohorts of the Phase 1b portion of the Phase 1b/Phase 2 clinical trial of AVB-500 in patients with platinum-resistant recurrent ovarian cancer (PROC) and unanimously recommended the study continue as planned with enrollment of patients into the 20mg/kg dose cohorts. The DMC did not identify any safety concerns with AVB-500....The company anticipates reporting safety and pharmacokinetic data from this Phase 1b trial in mid-2020 with plans to present preliminary efficacy in 2H 2020. The company plans to initiate a randomized Phase 2/3 study in PROC by end of 2020."Lynparza (olaparib) / Merck (MSD), AstraZenecaL-MOCA: Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy (clinicaltrials.gov) - Feb 18, 2020 - P3; N=19; Active, not recruiting; Sponsor: AstraZeneca; N=240 --> 19Keytruda (pembrolizumab) / Merck (MSD); Abraxane (albumin-bound paclitaxel) / Otsuka, BMS; relacorilant (CORT125134) / Corcept TherapCorcept Therapeutics announces fourth quarter and full-year 2019 audited financial results and provides corporate update (GlobeNewswire, Corcept Therapeutics Incorporated) - Feb 20, 2020 - "Solid Tumors: (i) Controlled, Phase 2 trial of relacorilant plus nab-paclitaxel to treat metastatic ovarian cancer actively enrolling patients at sites in the United States and Europe, on track to produce results in first half of 2021; (ii) Phase 3 trial of relacorilant plus nab-paclitaxel to treat patients with metastatic pancreatic cancer to start in second quarter; (iii) Phase 1b trial of relacorilant plus the immunotherapeutic agent pembrolizumab (Keytruda®) to treat patients with metastatic or unresectable adrenocortical cancer to start in second quarter."Zepsyre (lurbinectedin) / PharmaMar, JazzZepsyre: Protection of use patent in US/EU until 2031 (Pharmamar) - Feb 20, 2020 - Corporate Presentation: Protection of composition-of-matter patent in US/EU until 2024/2022 [Screenshot]tisotumab vedotin (HuMax-TF-ADC) / Genmab, Seattle GeneticsTisotumab vedotin: Expiry of patents in US and EU between 2022 and 2032 (Seattle Genetics, Inc) - Feb 16, 2020 - Annual Report 2019pamiparib (BGB-290) / EMD Serono; AiTan (rivoceranib) / HLB Bio GroupHengrui files for new indication for apatinib, gets trial nod for PARPi (GBI Health) - Feb 17, 2020 - "China’s Jiangsu Hengrui Medicine Co., Ltd (600276.SH) announced its is seeking market approval for a new indication for the Category 1 drug apatinib. A related filing has been accepted for review by the National Medical Products Administration (NMPA). The aim is to allow apatinib to be used against advanced hepatocellular carcinoma (HCC) unresponsive to or intolerable of first-line and above systemic therapies...Meanwhile, the company got the green light from the NMPA to carry out a Phase III clinical study for its poly adp-ribose polymerase-1 (PARP-1) inhibitor pamiparib as a monotherapy or in combination with apatinib as maintenance treatment in first-line platinum-containing chemotherapy for advanced ovarian cancer."
